Nalidixic acid

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Nalidixic acid is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1964. DrugCentral lists 3 molecular targets, including HTR2B, PKM and gyrA|gyrB. Recorded indications include Bacterial urinary infection.

• Approval status: ofm (first approved 1964 by the FDA).
• Molecular targets: HTR2B, PKM and gyrA|gyrB (3 listed in DrugCentral).
• Indications: Bacterial urinary infection.
• ATC code: J01MB02 (Other quinolones).
• Molecular formula: C12H12N2O3; molecular weight 232.24 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Bacterial urinary infection

Contraindications (12)

• Acute nephropathy
• Anemia due to enzyme deficiency
• Deficiency of glucose-6-phosphate dehydrogenase
• Disease of liver
• Disorder of the central nervous system
• Peripheral nerve disease
• Porphyria
• Pseudomembranous enterocolitis
• Seizure disorder
• Severe Cerebral Arteriosclerosis
• Tendinitis
• Traumatic rupture of tendon

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
5-hydroxytryptamine receptor 2B	HTR2B	unknown	IC50 5.10
Pyruvate kinase PKM	PKM	unknown	IC50 4.28
DNA gyrase	gyrA|gyrB	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1964-03-06	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
J01MB02	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › QUINOLONE ANTIBACTERIALS › Other quinolones

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: G6PD · Actionable PGx
• PMDA label: G6PD · Actionable PGx

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Nalidixic acid is on its molecule page.

• Molecular formula: C₁₂H₁₂N₂O₃
• Molecular weight: 232.24 g/mol
• CAS number: 389-08-2
• InChIKey: MHWLWQUZZRMNGJ-UHFFFAOYSA-N
• PubChem CID: 4421

CCN1C=C(C(O)=O)C(=O)C2=CC=C(C)N=C12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nalidixic acid used for?

DrugCentral lists the following indications for Nalidixic acid: Bacterial urinary infection.

How does Nalidixic acid work?

Its molecular targets in DrugCentral include HTR2B, PKM and gyrA|gyrB (inhibitor).

When was Nalidixic acid first approved?

Nalidixic acid was first approved by the FDA in 1964.

What is the chemical formula of Nalidixic acid?

Nalidixic acid has the molecular formula C12H12N2O3 and a molecular weight of 232.24 g/mol.

Sources

• DrugCentral drug card 1875 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL5 — compound record and bioactivity
• PubChem CID 4421 — chemical identifiers
• DrugBank DB00779 — drug record
• FDA UNII 3B91HWA56M — substance identity
• DailyMed: FDA labels for Nalidixic acid — current prescribing information (label search)
• UniProt P41595 (HTR2B) — target protein
• UniProt P14618 (PKM) — target protein
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.